OMER OMEROS CORP
Pharmaceutical Preparations · Nasdaq · SEC CIK 1285819 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY181.2%
TTM EPS YoY176.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR70.1%
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA45.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets136.3%
Debt / equity—
Current ratio2.27x
Interest coverage-1.47x
Cash quality & payout
Operating cash flow / net income-0.38x
Accruals ratio62.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $81.30M | $119.52M |
| SG&A expense | $41.50M | $47.43M |
| Operating income | -$122.80M | -$166.95M |
| Interest expense | -$960,000 | $24.68M |
| Pretax income | -$2.80M | -$180.32M |
| Income tax | $2.01M | $2.31M |
| Net income | -$3.35M | -$156.81M |
| EBITDA | -$121.83M | -$166.00M |
| EPS (basic) | -0.05 | -2.70 |
| EPS (diluted) | -0.05 | -2.70 |
| Balance sheet | ||
| Cash & equivalents | $9.66M | $3.40M |
| Short-term investments | $162.14M | $86.73M |
| Receivables | $0 | $7.74M |
| Inventory | $0 | — |
| Current assets | $215.67M | $134.12M |
| PP&E, net | $1.77M | $2.68M |
| Total assets | $325.63M | $277.08M |
| Current liabilities | $78.06M | $79.53M |
| Long-term debt | $51.36M | $164.90M |
| Total debt | $51.36M | $164.90M |
| Total liabilities | $446.86M | $459.69M |
| Shareholders' equity | -$121.23M | -$182.61M |
| Net debt | $41.70M | $161.50M |
| Shares outstanding | 71.67M | 58.04M |
| Cash flow statement | ||
| Operating cash flow | -$116.09M | -$148.80M |
| Capital expenditure | $65,000 | $165,000 |
| Free cash flow | -$116.16M | -$148.97M |
| Investing cash flow | $164.52M | $82.22M |
| Financing cash flow | -$42.17M | $62.88M |
| Depreciation & amortization | $964,000 | $950,000 |
| Stock-based compensation | $8.19M | $10.49M |
| Share buybacks | $0 | $11.85M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.